RNA, U6 small nuclear 724, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-724P profile across patient tissues and cancer cell-line models. RNU6-724P expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, RNU6-724P is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, RNU6-724P RNA expression shows 7,467 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight STAD, LUSC, and LUAD as cancer lineages where RNU6-724P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-724P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-724P survival associations across molecular data types. RNU6-724P RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-724P RNA expression–survival associations across cancer types. High RNU6-724P expression shows unfavorable associations in STAD, COAD, HNSC and MESO, but favorable associations in OV and LUAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for RNU6-724P RNA expression.
This table summarizes RNU6-724P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-724P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-724P shows lower tumor expression in LUSC and THCA and higher tumor expression in PRAD and BRCA. The LUSC box plot shows higher RNU6-724P RNA expression in normal versus tumor tissue (log2 FC = −0.592, t-test p < 0.001).
This table shows molecular features associated with RNU6-724P in patient tissues and cancer cell lines. In patient samples, RNU6-724P shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
